Award notice · Contracts Finder
Oncotype DX Breast Cancer Testing
Part of Oncotype DX Breast Cancer Testing.
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
- Procurement
- Oncotype DX Breast Cancer Testing
- Published
- 3 Mar 2026
- Status
- complete
- CPV
- 85111800 — Pathology services
- Tender period
- — – 4 Feb 2026
Awards
Other notices in this procurement
This is the only notice on record.
FAQs about this notice
What type of notice is this?
This is a award notice published via Contracts Finder on 3 Mar 2026.
Which procurement does this notice belong to?
It is part of "Oncotype DX Breast Cancer Testing", published by East Sussex Healthcare NHS Trust.
Has this notice resulted in an award?
1 award is recorded on this notice, including to Exact Sciences UK, Ltd..
Get the full procurement picture
Enable turns the UK's public-contract data into pipeline intelligence for bid and capture teams. Talk to us about access, alerts and tailored market analysis.
Get in touch with Enable